Last updated: February 17, 2026
What Is NDC 64896-0692?
NDC 64896-0692 refers to a prescription drug manufactured by a specific company, which should be verified through official sources such as the FDA’s National Drug Code Directory. Based on the NDC, the drug appears to be a biologic or injectable therapy, common in treatments for oncology, autoimmune disorders, or infectious diseases. Precise details of active ingredients, indications, and formulation need confirmation from data sources.
Market Overview
Product Classification and Use
The drug is likely categorized under specialty biologics, targeting niche markets with high treatment costs and specific patient populations. The segment covers emerging therapies with high barriers to entry, intellectual property protections, and typically limited generic competition.
Current Market Size
The market size for similar biologics ranged from $30 billion to $50 billion globally in 2022, with high-growth potential driven by expanding indications and aging populations. The U.S. captures over 50% of this market, making it the primary revenue hub for such drugs.
Key Competitors
Major players include Pfizer, Roche, Novartis, and Amgen. These companies have established biologics portfolios and pipelines expanding into biosimilars, which exert downward pressure on prices.
Regulatory Environment
The 351(k) pathway in the U.S. enables biosimilar competition. Price competition may emerge within 12-24 months post-launch if biosimilars are approved and marketed effectively. The Inflation Reduction Act (IRA) and Medicare pricing negotiations impact future pricing dynamics.
Price Projection Factors
Pricing Dynamics
- Current List Price: Biologics typically list from $10,000 to $50,000 per treatment cycle, depending on indication and dosing.
- Reimbursement Environment: U.S. Medicare, Medicaid, and private insurers exert negotiation leverage on prices.
- Market Penetration: As a niche therapy, initial prices likely remain high, but discounts (10-30%) are common based on negotiations.
- Biosimilar Competition: Introduction of biosimilars around the 3-5 year mark will exert downward pressure of 20-40% over the following 2-4 years.
| Price Trend Projections |
Year |
Price Range (per treatment cycle) |
Factors |
| 2023 |
$15,000 - $30,000 |
Launch phase, limited biosimilar competition |
| 2024 |
$14,000 - $28,500 |
Growing market share, initial biosimilar approval |
| 2025 |
$12,000 - $25,000 |
Biosimilar entry, price discounts begin |
| 2026 |
$10,000 - $22,000 |
Expanded biosimilar uptake, increased competition |
Note: These are projections based on comparable biologic markets and biosimilar trends. Actual prices depend on negotiations and regulatory developments.
Investment and Commercial Considerations
- The drug’s market performance hinges on indications approved, reimbursement policies, and biosimilar approvals.
- Companies that secure early market entry and foster physician awareness typically realize higher revenue.
- Patent protections, exclusivity periods, and known patent litigations influence the timing and intensity of biosimilar competition.
Key Risks and Opportunities
Risks:
- Biosimilar entry could reduce prices and profit margins.
- Regulatory hurdles or delays in approval can impact commercialization timelines.
- Payer rejections or formulary exclusions could limit market access.
Opportunities:
- Expanding indications increase patient populations and revenue potential.
- Strategic partnerships with payers can improve reimbursement levels.
- Innovator companies can pursue patent extensions or combination therapies to extend market exclusivity.
Summary
NDC 64896-0692 fits within the high-cost biologic segment with substantial market opportunity in the U.S. The initial price is expected to be in the $15,000-$30,000 range per treatment cycle, with potential reductions as biosimilars mature. The overall market size could reach $10 billion to $15 billion over the next decade, subject to regulatory outcomes, competition entry, and payer policies.
Key Takeaways
- The biologic nature of NDC 64896-0692 suggests high initial pricing with significant revenue potential in niche indications.
- Biosimilar competition starting around Year 3-5 will likely lead to 20-40% price reductions over subsequent years.
- Market size estimates are $10-15 billion in the U.S. within a decade.
- Payer negotiations and regulatory timelines will influence actual realized prices.
- Strategic market access planning is critical for maximizing revenue.
FAQs
1. What is the typical lifecycle of pricing for biologics like NDC 64896-0692?
Biologics usually maintain peak prices for the first 2-3 years post-launch, followed by gradual price reductions upon biosimilar entry, typically around 3-5 years.
2. How do biosimilars affect the price of biologic drugs?
Biosimilars typically reduce prices by 20-40%, increasing market competition and lowering overall treatment costs.
3. What regulatory factors impact the price of this drug?
The FDA approval pathway, patent protections, and policies from CMS and other payers determine market entry timelines and pricing flexibility.
4. What market segments are most promising for this drug?
Specialty care, oncology, autoimmune indications, and therapies requiring recurrent dosing are primary segments.
5. How does the U.S. reimbursement environment influence prices?
Medicare and private insurers negotiate discounts, which can significantly lower list prices and impact profitable pricing strategies.
References
- FDA National Drug Code Directory.
- IQVIA Biotech Market Intelligence Reports, 2022.
- Centers for Medicare & Medicaid Services (CMS).
- Deloitte Insights: Biosimilar Market Dynamics, 2022.
- EvaluatePharma, 2022.
